Drug Trial Radar · NCT06742333
Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation?
Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Jul 22, 2025
Primary completion
Jul 22, 2028
Study completion Jan 1, 2029
Sponsor
- Lead sponsor
- Centre Hospitalier Universitaire de NiceAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Psoriasis is a chronic inflammatory condition driven by a complex interplay between heritable and microenvironmental factors. Genome-wide heritability for psoriasis (PsO) is estimated at up to 50%. Although bearing genetic susceptibility at birth, most patients will remain disease free for years until an exposomal trigger activates the immunological pathway that leads to the first disease flare. In rare patients, the first flare is an isolated event, but in most patients it will evolve into a chronically relapsing-remitting disease characterized by lasting lesions and recurrent flares. Primary objective is to compare efficacy of bimekizumab versus topical corticosteroids on psoriasis clinical disease activity, assessed by PGA, at week 16 and week 24. Patients will be randomized 1:1 to receive either 320mg bimekizumab at weeks 0 (W0), W4, W8 and W12, or clobetasol ointment for 2 to 4 weeks until complete clearance of the lesion. After a maximum of 4 weeks topical clobetasol will be applied twice weekly on the site of lesion until week 16 then stopped. Patients will not receive active treatment between week 16-24. Between week 24-96 patients that flare can receive continuous topical clobetasol if needed. These patients will be considered non-responders at subsequent timepoints for the main analysis. If the patients worsen their psoriasis under the treatments given during the study and progress to moderate or severe psoriasis (PASI 10 and above) they will end their participation to the study to receive a treatment adapted to the new severity of their psoriasis. The patients will be referred to their dermatologist to receive the actual standard of care adapted to their new condition. During the study, the following assessments will be performed and samples will be collected
Conditions
- Psoriasis
Interventions
BimekizumabDrug
Bimekizumab 320mg given at weeks wk0, wk4, wk8 and wk12
ClobetasolDrug
Once daily evening application of 0.05% of clobetasol ointment for up to 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of bimekizumab versus topical corticosteroids on psoriasisTime frame: at 24 weeks
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Hôpital Edouard Herriot
Lyon, France · Recruiting
Hôpital Saint-Joseph
Marseille, France · Recruiting
Cabinet Dermatologie Dr RUER
Martigues, France · Recruiting
CHU Saint-Etienne
Saint-Etienne, France · Recruiting
CHITS
Toulon, France · Recruiting
Médipole Villeurbanne
Villeurbanne, France · Enrolling by invitation
CHU de Nice - Hôpital de l'Archet
Nice, Alpes-Maritimes, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.